

REMARKS

Favorable reconsideration is respectfully requested in view of the foregoing amendments and the following remarks. In order to expedite prosecution and without acquiescence to the correctness of the current rejections, all claims have been cancelled.

Thus, all rejections are moot.

Furthermore, during the interview with the Examiner on July 9, 2008, the Examiner indicated that a claim drawn to the particular embodiment shown in Example 9 on page 12 of the specification as filed should be allowable. Thus, in accordance with the Examiner's kind advice, Applicants herein present new claim 39 drawn to Example 9. Support can be found in this Example, particularly in Table 9 on page 12 of the specification.

The new claim 39 specifies the amounts of the components of the chewing gum composition. Applicants respectfully submit that Andersen (US 2004/0028772), Cherukuri et al. (US 4,238,510), Hill (US 5,380,530) and Johnson et al. (US 6,627,234) do not either alone or in combination teach or suggest each and every element of this new claim. These references only provide general guidance to a person of skill in the art investigating medicaments with cetirizine. The references fail to provide motivation to select the claimed components in the claimed amounts from the practically infinite components and amounts of components of the references. Thus, such references fail to render obvious the claimed invention.

In view of the foregoing amendments and remarks, it is respectfully submitted that the present application is in condition for allowance and early notice to that effect is hereby requested.

REMARKS

Favorable reconsideration is respectfully requested in view of the foregoing amendments and the following remarks. In order to expedite prosecution and without acquiescence to the correctness of the current rejections, all claims have been cancelled.

Thus, all rejections are moot.

Furthermore, during the interview with the Examiner on July 9, 2008, the Examiner indicated that a claim drawn to the particular embodiment shown in Example 9 on page 12 of the specification as filed should be allowable. Thus, in accordance with the Examiner's kind advice, Applicants herein present new claim 39 drawn to Example 9. Support can be found in this Example, particularly in Table 9 on page 12 of the specification.

The new claim 39 specifies the amounts of the components of the chewing gum composition. Applicants respectfully submit that Andersen (US 2004/0028772), Cherukuri et al. (US 4,238,510), Hill (US 5,380,530) and Johnson et al. (US 6,627,234) do not either alone or in combination teach or suggest each and every element of this new claim. These references only provide general guidance to a person of skill in the art investigating medicaments with cetirizine. The references fail to provide motivation to select the claimed components in the claimed amounts from the practically infinite number of components in particular amounts of the cited references. Thus, such references fail to teach or suggest the claimed invention.

In view of the foregoing amendments and remarks, it is respectfully submitted that the present application is in condition for allowance and early notice to that effect is hereby requested.

If the Examiner has any comments or proposals for expediting prosecution, please contact the undersigned attorney at the telephone number below.

Respectfully submitted,

Domenico FANARA et al.

By: William Schmidt
William Schmidt Reg. No. 58,327
- for -
Warren M. Cheek
Registration No. 33,367
Attorney for Applicants

WMC/WRS/lc
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
August 28, 2008